Acurx Pharmaceuticals, Inc.
NCM: ACXPLive Quote
📈 ZcoreAI Score
Our AI model analyzes Acurx Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ACXP Z-Score →About Acurx Pharmaceuticals, Inc.
Healthcare
Biotechnology
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
📊 Fundamental Analysis
Acurx Pharmaceuticals, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -270.8%, which indicates that capital utilization is currently under pressure.
At a current price of $2.61, ACXP currently trades near the bottom of its 52-week range (7%), indicating potential value or weakness (Range: $1.33 - $21.00).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$7.45M
Trailing P/E
--
Forward P/E
-1.19
Beta (5Y)
-1.92
52W High
$21.00
52W Low
$1.33
Avg Volume
3.20M
Day High
Day Low